OTCMKTS:FSNUY

Fresenius SE & Co. Q3 2025 Earnings Report

Fresenius SE & Co. logo
$11.27 +0.18 (+1.58%)
As of 06/18/2026 03:59 PM Eastern

Fresenius SE & Co. EPS Results

Actual EPS
$0.23
Consensus EPS
$0.21
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A

Fresenius SE & Co. Revenue Results

Actual Revenue
$6.29 billion
Expected Revenue
$6.38 billion
Beat/Miss
Missed by -$93.12 million
YoY Revenue Growth
N/A

Fresenius SE & Co. Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Fresenius SE & Co.'s next earnings date is estimated for Wednesday, August 5, 2026, based on past reporting schedules.

Conference Call Resources

Fresenius SE & Co. Earnings Headlines

Fresenius SE & Co. KGaA (0OO9) Receives a Buy from Barclays
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.tc pixel
Fresenius SE Earnings Call Highlights Growth Momentum
See More Fresenius SE & Co. Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresenius SE & Co.? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresenius SE & Co. and other key companies, straight to your email.

About Fresenius SE & Co.

Fresenius SE & Co. (OTCMKTS:FSNUY) KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co. brings together a portfolio of specialized healthcare businesses under one corporate umbrella.

The company operates through four main business segments. Fresenius Medical Care is the largest provider of renal care products and services, including dialysis machines, disposables and clinic operations. Fresenius Kabi offers a broad range of lifesaving medicines, infusion therapies, clinical nutrition and medical devices for intravenous drug delivery. Fresenius Helios manages a network of acute care hospitals and outpatient facilities across Europe, while Fresenius Vamed specializes in planning, construction and management of healthcare projects and facilities, supporting clients from conception through operation.

Fresenius serves patients and healthcare providers in more than 100 countries, with production sites, research centers and clinical operations spanning Europe, North America, Asia-Pacific and Latin America. The company emphasizes continuous innovation, investing in research and development to enhance patient outcomes and streamline care delivery. Under the leadership of Chief Executive Officer Dr. Stephan Sturm, Fresenius pursues a strategy of geographic expansion and portfolio optimization to address evolving global healthcare needs.

View Fresenius SE & Co. Profile